American Society of Cytopathology Core Curriculum in Molecular Biology

Similar documents
MEDICAL POLICY SUBJECT: URINARY TUMOR MARKERS FOR BLADDER CANCER. POLICY NUMBER: CATEGORY: Technology Assessment

Urinary Cytology. Spasenija Savic Prince Pathology, University Hospital Basel, Switzerland

Application of Urovision FISH testing for diagnosis of bladder cancer

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Corporate Medical Policy

Urinary Cytology. Spasenija Savic Prince, MD Pathology, University Hospital Basel, Switzerland

BLADDER CANCER: PATIENT INFORMATION

Yavuz Dodurga 1, ÇIğIr Biray AvcI 2, Sunde YIlmaz 2, Oktay NazlI 3, Özgür Çoğulu 4, Tufan Cankaya 5, Cumhur Gündüz 2. Introduction

Quantitative Fluorescence in Situ Hybridization and its Ability to Predict Bladder Cancer Recurrence and Progression to Muscle-Invasive Bladder Cancer

Afterword: The Paris System for Reporting Urinary Cytology

A novel urine cytology stain for the detection and monitoring of urothelial carcinoma

Vysis ALK Break Apart FISH Probe Kit

The application of cytology in urological diseases

HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer

Efficient and Effective Use of Exfoliative Markers

HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer

Oncology Genetics: Cytogenetics and FISH 17/09/2014

Bladder Cancer Diagnostic Tests

Bladder Cancer Early Detection, Diagnosis, and Staging

Urinary Biomarkers for Cancer Screening, Diagnosis, and Surveillance

Rationale of The Paris System for Reporting Urinary Cytopathology: The NEW paradigm

Protocol. Urinary Tumor Markers for Bladder Cancer

Staging and Grading Last Updated Friday, 14 November 2008

American Society of Cytopathology Core Curriculum in Molecular Biology

Correspondence should be addressed to Tilman Todenhöfer;

Attachment #2 Overview of Follow-up

UroVysion Compared with Cytology and Quantitative Cytology in the Surveillance of Non Muscle-Invasive Bladder Cancer

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

Biliary Tract Malignancy-Cyto/FISH

IT S ABOUT TIME. IQFISH pharmdx Interpretation Guide THREEHOURSTHIRTYMINUTES. HER2 IQFISH pharmdxtm. TOP2A IQFISH pharmdxtm

Related Policies None

Combining Color and Morphology Improves Identification of Low-Grade Urothelial Cancer Cells

Bladder Cancer Canada November 21st, Bladder Cancer 2018: A brighter light at the end of the cystoscope

December 22, Earl Berman, MD Attn Medical Review Two Vantage Way Nashville, TN

비뇨병리연구회공청회 조남훈 연세대학교병리학교실

at least 5 probes standard 8 probes (13, 15, 16, 18, 21, 22, 15, X, Y) at least 5 probes standard 8 probes (13, 15, 16, 18, 21, 22, X, Y)

Attachment #2 Overview of Follow-up

The merits of cytology in the workup for upper tract urothelial carcinoma - a contemporary review of a perplexing issue

Issues in the Management of High Risk Superficial Bladder Cancer

Role of FISH in Hematological Cancers

Conflict of Interest. Thank you. I have no relevant conflicts of interest in regards to the content of this presentation.

Kidney, Bladder and Prostate Neoplasia. David Bingham MD

Original Policy Date

B. PURPOSE The purpose of this policy is to define the workflow and process involved with the procurement of Fine Needle Aspirations.


Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016

Effective Health Care Program

Toyonori Tsuzuki MD, PhD Professor and Chair Department of Surgical Pathology Aichi Medical University Hospital

Instructions for Use. APO-AB Annexin V-Biotin Apoptosis Detection Kit 100 tests

Urinary Bladder: WHO Classification and AJCC Staging Update 2017

Anti-hTERT Antibody (SCD-A7)

ZytoFast CMV Probe (Biotin-labeled)

Carcinoma of the Renal Pelvis and Ureter Histopathology

Citation International journal of urology (2. Right which has been published in final f

Diagnosis and classification

MEDitorial March Bladder Cancer

The difference in cancer detection

Reviewing Immunotherapy for Bladder Carcinoma In Situ

Dako IT S ABOUT TIME. Interpretation Guide. Agilent Pathology Solutions. ALK, ROS1 and RET IQFISH probes (Dako Omnis) MET IQFISH probe (Dako Omnis)

Point-Counterpoint: Radiation & Bladder Cancer

A patient with recurrent bladder cancer presents with the following history:

Urine Markers for Bladder Cancer. Peter Black, MD, FACS, FRCSC Khosrowshahi Family Chair Vancouver Prostate Centre University of British Columbia

Three Hours Thirty Minutes

Breast Cancer Interpretation Guide

Instant Quality FISH. The name says it all.

Educator Navigation Guide

Tier 3: The effectiveness of urinary biomarker genotypes (Cxbladder Detect) in the investigation of haematuria in Primary Care

Upper Tract Urothelial Carcinomas (UTUCs)

INTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein

6/5/2010. Renal vein invasion & Capsule Penetration (T3a) Adrenal Gland involvement (T4 vs. M1) Beyond Gerota s Fascia? (?T4).

ABBOTT MOLECULAR ONCOLOGY AND GENETICS

Assessment of Breast Cancer with Borderline HER2 Status Using MIP Microarray

Pathology Specimen Handling Requirements

Updates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency

Abstract. Anatomic Pathology / DETECTING PANCREATOBILIARY TRACT MALIGNANCY

Electron Microscopy Sciences

ACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI

BLADDER CANCER EPIDEMIOLOGY

Providence Medford Medical Center Pathology Department

How Many Diseases in Carcinoma in situ?

Exercise 6. Procedure

LAB EXPERIMENT 4: Mitosis in Onion Root Tip Cells

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer

5/26/16: CT scan of the abdomen showed a multinodular liver disease highly suspicious for metastasis and hydronephrosis of the right kidney.

A NOVEL URINE CYTOLOGY STAIN FOR THE DETECTION AND MONITORING OF UROTHELIAL CARCINOMA. Running head: A Novel Stain For The Detection Of Bladder Cancer

Can Use the NMP22 BladderChek Decrease the Frequency of Cystoscopy in the Follow up of Patients with Bladder Carcinoma?

Controversies in the management of Non-muscle invasive bladder cancer

Urinary Bladder, Ureter, and Renal Pelvis

MECHANISMS OF HUMAN DISEASE: LABORATORY SESSION CYTOPATHOLOGY Monday, April 26, 2013 FACULTY COPY

Cytogenetics 101: Clinical Research and Molecular Genetic Technologies

The use of Urovysiont fluorescence in situ hybridization in the diagnosis and surveillance of non-urothelial carcinoma of the bladder

UTILITY OF NMP22 BLADDERCHEK POINT-OF- CARE ASSAY IN EVALUATION OF HEMATURIA: A MULTICENTER STUDY

From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport

NMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland

Glossary of Terms Primary Urethral Cancer

Should We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis?

The innovative aspect is that it detects bladder cancer based on the novel biomarker, minichromosome maintenance complex component 5 (MCM5).

Transcription:

American Society of Cytopathology Core Curriculum in Molecular Biology

American Society of Cytopathology Core Curriculum in Molecular Biology Chapter 6 Fluorescence in situ Hybridization (FISH) Principles and Preparatory Techniques Amy Wendel Spiczka, M.S. SCT, MB, HTL (ASCP) CM Mayo Clinic Scottsdale, Arizona Kara Hansing, SCT (ASCP) CM Mayo Clinic Rochester, Minnesota

Objectives Describe use of FISH in the detection of neoplasia Characterize the stepwise progression through the FISH preparation process, detailing what is happening at the molecular level for each step

Outline of Presentation Background FISH & Urothelial carcinoma Development & validation of UroVysion test How to perform the test

FISH Current & Future Opportunities FISH, as a technique, continues to have an increasingly integral role in cytology laboratories Cytotechnologists, pathologists, and clinicians need to have an essential understanding the role FISH plays in detecting neoplasia and in guiding the management of patients who have cancer FISH frequently has higher sensitivity than conventional cytology FISH may detect tumor cells in cytologic specimens that cannot be detected by conventional methods

What is FISH? FISH = Fluorescence in situ Hybridization Utilizes fluorescently labeled DNA probes that hybridize (stick to) specific chromosomal loci Technique that allows detection of chromosomal alterations in cells

FISH is a Type of Cytology FISH is a unique way to examine cells One examines cells for morphologic features typical of neoplasia (e.g., nuclear enlargement, nuclear irregularity, etc.), and chromosomal abnormalities indicative of neoplasia

FISH is an Excellent Tool to Detect Cancer as Tumors have Chromosomal Abnormalities Normal Karyotype Normal cells have 46 chromosomes (visible only during mitosis) Karyotype of a Cancer Cell Tumor cells frequently have abnormal numbers of chromosomes (aneuploidy) & chromosomal structural abnormalities Images Courtesy of FISH Education Mayo Cytogenetics Laboratory

FISH Probes Centromeric probes Hybridize to (i.e. attach to) specific chromosomal centromeres Locus specific probes Hybridize to other regions of chromosome Usually designed to hybridize to specific gene regions

UroVysion Probe Set CEP 3 LSI 9p21 CEP 7 CEP 17 Original Image Courtesy of FISH Education Mayo Cytogenetics Laboratory

FISH Probes Centromeric probes Allows one to count the number of copies of a chromosome in a cell Why? Because if you lose the centromere of a chromosome, you lose the whole chromosome Locus specific probes Deletions or gains of specific gene regions

Cytologic Applications of FISH Urothelial carcinoma (urine) Biliary tract malignancy (biliary tract brushings) Barrett s esophagus (endoscopic brushings) Cervical cancer (cervical cytology) Lung cancer (bronchoscopic brushings and secretions, sputum)

Urothelial Cell Carcinoma (UCC) ~55,000 cases/year ~12,500 deaths Very high prevalance ~500,000 (U.S.) One of the most expensive cancers to diagnose and treat

Urothelial Carcinoma Papillary UC ~80% of all UC Tends to recur but not progress to invasion Most are grade 1 and 2 tumors Flat UC (CIS) ~20% of all UC More aggressive, tends to progress to invasive tumor High grade tumors

Papillary UCC

In situ or flat UCC

Treatment of UCC Muscle invasive Cystectomy or nephroureterectomy Superficial Excision, fulguration, BCG, other Monitoring for tumor recurrence Cystoscopy and cytology

Surveillance for Superficial UCC Cystoscopy 0 2 years: Every 3 months 2 4 years: Every 6 months 5 on: Yearly Cytology Obtained at time of cystoscopy

Pros & Cons of Cystoscopy vs. Cytology Cystoscopy Detects papillary UC Sometimes misses flat UC Cytology Detects most flat UC (high grade) Frequently misses papillary UC (low grade) Overall low sensitivity

Sensitivity of Cytology for UC by Grade (Review of Literature) Grade 1 Grade 2 Grade 3 Studies before 1990 (n = 4) 37% 75% 94% Studies from 1990 on (n = 16) 11% 31% 60% All studies 21% 53% 78% Halling et al., J Urol;164:1768, 2000

Laboratory Detection of UCC Cytology Antigen based methods BTA stat, NMP22, Immunocyt, Molecular genetic methods Telomerase, microsatellite analysis DNA ploidy analysis (flow cytometry/dia) Molecular cytogenetic methods (FISH)

FISH for the Detection of Urothelial Carcinoma Mayo Clinic began working on the development of a FISH assay for the detection of UC in 1998 (in collaboration with Abbott Molecular) This led to a multi target, multi color FISH probe set for the detection of recurrent UC which is now referred to as UroVysion Sokolova et al., J Mol Diagn;2:3, 2000

UroVysion Probes CEP 3 (red) CEP 7 (green) CEP 17 (aqua) LSI 9p21 (gold)

UroVysion These 4 probes chosen from 11 candidates The use of a multi probe cocktail increases both the sensitivity and specificity of the assay over single or dual probes

UroVysion (Normal Cell) CEP 3 CEP 7 CEP 17 LSI 9p21

UroVysion (Malignant Cell) CEP 3 CEP 7 CEP 17 LSI 9p21

Sensitivity of Cytology and FISH: Overall and by Stage* pta ptis pt1 pt4 All Tumors Cytology 17/36 (47%) 14/18 (78%) 9/15 (60%) 40/69 (58%) FISH 24/37 (65%) 17/17 (100%) 18/19 (95%) 59/73 (81%) P value 0.058 0.046 0.025 0.001 *75 biopsy proven UC patients Halling et al., J Urol, 2000

Sensitivity of Cytology and FISH: Overall and by Grade Grade 1 Grade 2 Grade 3 All Tumors Cytology 3/11 (27%) 13/24 (54%) 24/34 (71%) 40/69 (58%) FISH 4/11 (36%) 19/25 (76%) 36/37 (97%) 59/73 (81%) P value 0.564 0.034 0.003 0.001 Halling et al., J Urol, 2000

FISH is more Sensitive than Conventional Urine Cytology Weighted Mean 100 90 80 70 60 50 40 30 20 10 0 Cytology FISH Ta T1 T2-4 TIS Grade 1 Grade 2 Grade 3 Overall Sensitivity Specificity

UroVysion FDA approved for: Detection of recurrent tumor in patients with a history of bladder cancer (2001) Evaluation of patients with hematuria for bladder cancer (2005)

Performing the FISH Test: Focus on Lab Preparation

FISH Urine Testing Overview 1. Obtain urine sample 2. Isolate cells from urine and place on slide (slide preparation) 3. Prepare cells for FISH hybridization (prehybridization) 4. Hybridize FISH probes to cells 5. Assess cells for chromosomal abnormalities using fluorescence microscope

Specimen Types Voided urine (FDA approved) Catherized urine Bladder washings Upper tract washings (ureters and renal pelvis) Stomal specimens Previously stained ThinPrep slides

Preservatives Ethanol/Methanol of varying concentrations PreservCyt and CytoLyt Fresh Specimen (no preservative)

UroVysion Slide Preparation Manual method (Abbott Molecular package insert) ThinPrep 2.0 cm diameter (Non gyn filters) 1.0 cm diamter (UroCyte filter) Cytospin

Slide Preparation (Abbott Molecular Method) Cells sedimented in a centrifuge and washed with PBS buffer and fixative Cells resuspended in small volume (<0.5mL) of residual fixative Portion of this cell suspension (~10ul) dropped on a slide

Slide Preparation (Abbott Molecular Method) Cellularity of slide assessed with phase contrast microscope If necessary, additional cell suspension is added to get the desired result What is the desired result? To get as many cells as possible on slide without having much cell overlap

Slide Preparation (Abbott Molecular Method) Copyright 2010 American Society of Cytopathology to you by

Slide Preparation (Abbott Molecular Method) Some limitations with this method Time consuming Inconsistent cell dropping between different technologists Hard to assess cellularity under phase contrast scope in specimens with a lot of debris (i.e. crystals, proteinaceous debris, etc.)

Slide Preparation (ThinPrep) Alternative preparation method ThinPrep 2.0 cm slide Problems Cells spread over too large a surface area Requires 10ul of UroVysion probe Markedly increases time required to analyze slide Increased cost

Slide Preparation (ThinPrep) Another alternative method ThinPrep UroCyte filter/slide (1.0 cm) Recently developed filter/slide to be used for FISH urine processing Automates slide making for FISH Reduces area over which cells are spread (1.0 cm) Reduces amount of probe needed (3uL) and time required to analyze slide without the subjectivity of cell dropping

Slide Preparations Manual Gold Seal Slide Cytyc ThinPrep 2-cm NON-Gyn Slide/Filter Cytyc 1-cm ThinPrep UroCyte Slide/Filter

Prepare Cells for FISH Hybridization (Pre-hybridization) Pre hybridization treatment is necessary to allow the FISH probes to enter the cell and hybridize to their target loci Can use manual (Coplin jars) or automated (VP2000) method depending on number of specimens pre hybridized by your laboratory

VP2000

Pre-hybridization Steps Step Reagent Time (min) Temp (C) 1 2xSSC 2 73 2 Pepsin in HCL 10 37 3 PBS 5 RT 4 1% Form. 5 RT 5 PBS 5 RT 6 70% ETOH 1 RT 7 85% ETOH 1 RT 8 100% ETOH 1 RT 9 Air Dry 3 RT

Hybridization Following pre hybridization, 3uL of FISH probe is carefully dropped on the target area A small coverslip (22x22 square or 12 mm circle) is then placed on the area Rubber cement is placed around the coverslip to prevent evaporation of the probe

Hybridization The hybridization of the FISH probes can be competed in a humidified chamber and 37 C oven or on a Denaturation System

DAPI DAPI I vs. II There are unique formulas for DAPI DAPI II is the manufacturer recommended counterstain for most CEP and LSI probes. This concentration of DAPI provides weaker DAPI stain usually preferred with smaller probe signals such as CEP and LSI probes

Post-hybridization Following overnight hybridization Slides are washed in 2xSSC to remove probe that is not specifically bound Failure to do this long enough will result in background signals (starry sky pattern) DAPI counterstain added and slide cover slipped 4,6 diamidino 2 phenylindole

Please view the lecture FISH Analysis Learn to assess cells for chromosomal abnormalities using fluorescence microscopy

Thank you! Special recognition is given to Kevin Halling, M.D., Ph.D. and Ben Kipp, Ph.D. for the materials provided in this lecture